AR099079A1 - Variantes de región fc con propiedades de unión de fcrn modificadas - Google Patents
Variantes de región fc con propiedades de unión de fcrn modificadasInfo
- Publication number
- AR099079A1 AR099079A1 ARP150100075A ARP150100075A AR099079A1 AR 099079 A1 AR099079 A1 AR 099079A1 AR P150100075 A ARP150100075 A AR P150100075A AR P150100075 A ARP150100075 A AR P150100075A AR 099079 A1 AR099079 A1 AR 099079A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- immunoglobulin
- mutations
- domain
- modified fcrn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se comunica un polipéptido que comprende un primer polipéptido y un segundo polipéptido que comprende en dirección de N-terminal a C-terminal al menos una porción de una región bisagra de inmunoglobulina, que comprende uno o más restos de cisteína, un dominio CH2 de inmunoglobulina y un dominio CH3 de inmunoglobulina, en el que i) el primer y el segundo polipéptido comprenden las mutaciones H310A, H433A y Y436A, o ii) el primer y el segundo polipéptido comprenden las mutaciones L251D, L314D y L432D, o iii) el primer y el segundo polipéptido comprenden las mutaciones L251S, L314S y L432S. Reivindicación 1: Un polipéptido que comprende un primer polipéptido y un segundo polipéptido, comprendiendo cada uno en dirección de N-terminal a C-terminal al menos una porción de una región bisagra de inmunoglobulina, que comprende uno o más restos de cisteína, un dominio CH2 de inmunoglobulina y un dominio CH3 de inmunoglobulina, en el que i) el primer y el segundo polipéptido comprenden las mutaciones H310A, H433A y Y436A, o ii) el primer y el segundo polipéptido comprenden las mutaciones L251D, L314D y L432D, o iii) el primer y el segundo polipéptido comprenden las mutaciones L251S, L314S y L432S. Reivindicación 15: Una formulación farmacéutica que comprende un polipéptido de acuerdo con una cualquiera de las reivindicaciones 1 a 12 y opcionalmente un vehículo farmacéuticamente aceptable. Reivindicación 17: Un polipéptido de acuerdo con una cualquiera de las reivindicaciones 1 a 12 para su uso en el transporte de un ligando de receptor soluble desde el ojo a través de la barrera sangre-ocular a la circulación sanguínea.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14151319 | 2014-01-15 | ||
| EP14165922 | 2014-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099079A1 true AR099079A1 (es) | 2016-06-29 |
Family
ID=52462893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100075A AR099079A1 (es) | 2014-01-15 | 2015-01-13 | Variantes de región fc con propiedades de unión de fcrn modificadas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170037121A1 (es) |
| EP (1) | EP3094649A1 (es) |
| JP (2) | JP6873701B2 (es) |
| KR (1) | KR20160104009A (es) |
| CN (2) | CN105873948B (es) |
| AR (1) | AR099079A1 (es) |
| BR (1) | BR112016016411A2 (es) |
| CA (1) | CA2931979A1 (es) |
| HK (1) | HK1223951A1 (es) |
| MX (1) | MX2016008540A (es) |
| RU (1) | RU2730592C2 (es) |
| WO (1) | WO2015107025A1 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| KR101572338B1 (ko) | 2011-02-28 | 2015-11-26 | 에프. 호프만-라 로슈 아게 | 1가 항원 결합 단백질 |
| MX341921B (es) | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Proteinas de union a antigeno. |
| WO2014145159A2 (en) * | 2013-03-15 | 2014-09-18 | Permeon Biologics, Inc. | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use |
| CA2922912A1 (en) * | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
| EP4299595A3 (en) | 2014-05-02 | 2024-03-13 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP4015533A1 (en) * | 2015-10-29 | 2022-06-22 | F. Hoffmann-La Roche AG | Anti-variant fc-region antibodies and methods of use |
| JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| KR102590061B1 (ko) | 2016-05-23 | 2023-10-18 | 모멘타 파머슈티컬스 인코포레이티드 | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 |
| WO2018073185A1 (en) * | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Modified antibody constant region |
| SG10202107391YA (en) | 2017-01-06 | 2021-08-30 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| JP7374091B2 (ja) * | 2017-08-22 | 2023-11-06 | サナバイオ， エルエルシー | 可溶性インターフェロン受容体およびその使用 |
| EP3728327A1 (en) * | 2017-12-22 | 2020-10-28 | F. Hoffmann-La Roche AG | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
| CN110054700A (zh) * | 2018-01-18 | 2019-07-26 | 分子克隆研究室有限公司 | 长效治疗性融合蛋白 |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| JP2022512798A (ja) * | 2018-10-25 | 2022-02-07 | エフ．ホフマン－ラ ロシュ アーゲー | 抗体ＦｃＲｎ結合の改変 |
| KR102605376B1 (ko) | 2018-12-31 | 2023-11-23 | 삼성디스플레이 주식회사 | 표시 장치 |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP2022521750A (ja) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス，インコーポレーテッド | カルレティキュリンに結合する多機能性分子およびその使用 |
| JP2022521937A (ja) | 2019-02-21 | 2022-04-13 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| WO2020172571A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| AU2020224680A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES |
| CN115843312A (zh) | 2020-04-24 | 2023-03-24 | 马伦戈治疗公司 | 结合至t细胞相关癌细胞的多功能性分子及其用途 |
| AU2021288464A1 (en) * | 2020-06-08 | 2023-01-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-CD171 chimeric antigen receptors |
| CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230074144A (ko) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | NKp30에 결합하는 항체 분자 및 이의 용도 |
| WO2022047046A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
| EP4295154A1 (en) | 2021-02-18 | 2023-12-27 | F. Hoffmann-La Roche AG | Method for resolving complex, multistep antibody interactions |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| WO2022265331A1 (ko) * | 2021-06-14 | 2022-12-22 | 고려대학교 산학협력단 | 제어된 면역 작용 기작과 증가된 혈중 반감기를 갖는 fc변이체들 |
| CN117986383A (zh) * | 2022-11-02 | 2024-05-07 | 北京昌平实验室 | 融合蛋白及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| US7923538B2 (en) * | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| CA2665826A1 (en) * | 2006-10-16 | 2008-04-24 | Medimmune, Llc | Molecules with reduced half-lives, compositions and uses thereof |
| KR20120030383A (ko) * | 2009-04-22 | 2012-03-28 | 메르크 파텐트 게엠베하 | 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질 |
| CN103459422A (zh) * | 2010-11-24 | 2013-12-18 | 葛兰素集团有限公司 | 靶向hgf的多特异性抗原结合蛋白 |
| EP2661449B1 (en) * | 2011-01-06 | 2017-03-22 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| ES2774972T3 (es) * | 2011-10-13 | 2020-07-23 | Aerpio Therapeutics Inc | Tratamiento de enfermedades oculares |
| HRP20211773T1 (hr) * | 2011-11-04 | 2022-03-04 | Zymeworks Inc. | Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni |
| ES2843054T3 (es) * | 2012-05-10 | 2021-07-15 | Zymeworks Inc | Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc |
| JP6514103B2 (ja) * | 2012-07-06 | 2019-05-15 | ゲンマブ ビー．ブイ． | 三重変異を有する二量体タンパク質 |
| AU2014261631B2 (en) * | 2013-04-29 | 2019-02-14 | F. Hoffmann-La Roche Ag | FcRn-binding abolished anti-IGF-1R antibodies and their use in the treatment of vascular eye diseases |
| PL2992012T3 (pl) * | 2013-04-29 | 2019-12-31 | F. Hoffmann-La Roche Ag | Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania |
-
2015
- 2015-01-12 BR BR112016016411A patent/BR112016016411A2/pt not_active IP Right Cessation
- 2015-01-12 KR KR1020167019016A patent/KR20160104009A/ko not_active Application Discontinuation
- 2015-01-12 CA CA2931979A patent/CA2931979A1/en active Pending
- 2015-01-12 WO PCT/EP2015/050425 patent/WO2015107025A1/en active Application Filing
- 2015-01-12 CN CN201580003633.0A patent/CN105873948B/zh active Active
- 2015-01-12 CN CN202110445639.0A patent/CN113248613A/zh active Pending
- 2015-01-12 EP EP15703229.3A patent/EP3094649A1/en active Pending
- 2015-01-12 MX MX2016008540A patent/MX2016008540A/es unknown
- 2015-01-12 RU RU2016133345A patent/RU2730592C2/ru active
- 2015-01-12 JP JP2016546942A patent/JP6873701B2/ja active Active
- 2015-01-13 AR ARP150100075A patent/AR099079A1/es unknown
-
2016
- 2016-07-14 US US15/210,218 patent/US20170037121A1/en not_active Abandoned
- 2016-10-25 HK HK16112240.5A patent/HK1223951A1/zh unknown
-
2018
- 2018-04-06 US US15/947,377 patent/US20190016792A1/en not_active Abandoned
-
2021
- 2021-04-21 JP JP2021071749A patent/JP2021113214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016133345A3 (es) | 2018-10-31 |
| CN113248613A (zh) | 2021-08-13 |
| EP3094649A1 (en) | 2016-11-23 |
| RU2730592C2 (ru) | 2020-08-24 |
| RU2016133345A (ru) | 2018-02-20 |
| KR20160104009A (ko) | 2016-09-02 |
| JP2017505768A (ja) | 2017-02-23 |
| JP2021113214A (ja) | 2021-08-05 |
| BR112016016411A2 (pt) | 2017-10-03 |
| HK1223951A1 (zh) | 2017-08-11 |
| WO2015107025A1 (en) | 2015-07-23 |
| CN105873948B (zh) | 2021-04-13 |
| US20190016792A1 (en) | 2019-01-17 |
| US20170037121A1 (en) | 2017-02-09 |
| CN105873948A (zh) | 2016-08-17 |
| CA2931979A1 (en) | 2015-07-23 |
| JP6873701B2 (ja) | 2021-05-19 |
| MX2016008540A (es) | 2016-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099079A1 (es) | Variantes de región fc con propiedades de unión de fcrn modificadas | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| ZA202200648B (en) | Immunoglobulins and uses thereof | |
| CL2015002720A1 (es) | Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. | |
| MX2016008539A (es) | Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas. | |
| MX2020010061A (es) | Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso. | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| CO2017000754A2 (es) | Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo | |
| PE20151807A1 (es) | Anticuerpos modificados de union a fcrn humano y metodo de utilizacion | |
| MX361681B (es) | Composiciones de proteína estabilizadas basadas en alcanos semifluorados. | |
| CO2017004318A2 (es) | Variantes de interferon α2b | |
| BR112016014969A2 (pt) | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo | |
| EA201790895A1 (ru) | Модифицированные полипептиды fgf-21 и их применение | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
| PL397595A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| EA201591700A1 (ru) | Гибридные белки апелина и их применение | |
| MX2019002968A (es) | Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal. | |
| MX2021000030A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. | |
| CY1124911T1 (el) | Συνθεσεις πεπτιδιων και μεθοδοι χρησης | |
| UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
| AR099080A1 (es) | Variantes de región fc con propiedades de unión a fcrn (receptor fc neonatal) modificadas y de unión a proteína a mantenidas | |
| EA201991022A1 (ru) | Иммуноглобулины и их применение | |
| AR110106A1 (es) | Inmunoglobulinas y usos de estas | |
| Chowdhury et al. | Corrigendum to “Targeting the junction of CmX and-migis for the specific depletion of mIgE-expressing B cells”[Mol. Immunol. 52 (October–December (3–4))(2012) 279–288] |